AVIR

3.9600.76%
JS

Jean-Pierre Sommadossi

Founder, Chairman, CEO & President

Dr. Jean-Pierre Sommadossi, Ph.D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Sommadossi served as a Senior Advisor to the Chief Executive Officer at Athenex, Inc. since July 1, 2014. He co-founded Pharmasset, Inc. in 1998. He served as an Advisor at PureTech Health PLC until May 18, 2017. He founded Idenix Pharmaceuticals Inc. and served as its Chairman from 1998 to October 28, 2010, Executive President and Chief Scientific Officer from 1998 to 2000 and served as its President and Chief Executive Officer from November 2000 to October 28, 2010. Dr. Sommadossi serves as Chairman of Panchrest, Inc. since 2013 and a member the board of directors of The BioExec Institute. He served as a Vice Chairman of Rafael Pharmaceuticals, Inc. from October 2016 to November 2020 and as Chair of the board of directors of PegaOne, Inc from September 2020 to January 2021. Dr. Sommadossi serves as Advisory Board Member of ATEM Capital. He serves as Member of the Board of the BioExecutive Institute since 2004. He served as a Director of Alzheon Inc. from August 2014 to October 27, 2015. He was a Member of the Harvard Medical School Discovery Advisory Council from 2010 to 2021. Dr. Sommadossi served as Independent Chairman of Kezar Life Sciences, Inc. and board member since June 2015 until May 11, 2022. He served as a Director at Athenex, Inc. from June 5, 2012 to July 1, 2014. He served as an Associate Director of both the Center for AIDS Research and the Liver Center, University of Alabama at Birmingham School of Medicine from June 1992 to November 2000. From June 1992 to October 2000, he served as a Professor of pharmacology, toxicology and clinical pharmacology. Prior to this, Dr. Sommadossi was on the faculty of the University of Alabama at Birmingham School of Medicine since March 1985. He has authored over 180 peer-reviewed publications and holds more than 50 United States patents related to the treatment of cancer and infectious diseases. He was a postdoctoral Fogarty Fellow at the National Cancer Institute and the Medical College of Virginia and a recipient of a Faculty Award from The American Cancer Society. He has scientific, operational, strategic and management experience in the biotech industry. He founded Atea Pharmaceuticals in 2012. He served as a Director of Rafael Pharmaceuticals, Inc. He served as an Independent Director at ABG Acquisition Corp. since February 2021 until February 2023. He has been Chairman of BioThea Pharmaceuticals, Inc., since 2021. Dr. Sommadossi holds a Pharm.D. degree and a Ph.D. degree in Pharmacology from the University of Marseilles in France.

Positions